I lead R&D projects that are focused on translating discoveries related to the biology of aging and associated diseases. I work closely with Calico scientists and external partners to ensure scientific and operational success of programs through various stages of drug discovery and development.
I joined Calico from the Baylor Institute for Immunology Research in Dallas, where I was the Director of Therapeutic Development from 2012-2017, leading preclinical and early clinical development of a platform of dendritic cell-targeting therapeutic antibodies and fusion proteins for cancer and other indications. I also helped found Denceptor Therapeutics, a joint venture between Baylor and Abzena, which will further develop the platform. Prior to Baylor, I spent 7 years at Alcon (a Novartis company) as a Principal Scientist heading a discovery biology lab and leading early development teams focused on inflammation, allergy, and autoimmunity. I completed postdoctoral training in immunology and ophthalmology at Harvard Medical School and UT-Southwestern Medical Center.